Teva and UK Government Collaborate on New National Clinical Drug Development Initiative and Dementia ResearchBy
Teva Pharmaceutical Industries Ltd. has formed a collaboration with the United Kingdom (UK) Government's National Health Service National Institute for Health Research (NIHR) Office for Clinical Research Infrastructure (NOCRI).
The two-part collaboration follows the creation of an important new research infrastructure model by the UK's National Health Service (NHS), and was announced in the presence of UK Prime Minister, David Cameron, Israel Prime Minister, Binyamin Netanyahu, and Teva's President and CEO Erez Vigodman by Dr. Michael Hayden, Teva's President of global R&D and chief scientific officer, at a special UK-Israel Tech Hub at the British Embassy Israel event held at Teva's Jerusalem site.
NOCRI has created a novel model that streamlines the approach to undertaking clinical development in the UK. The new model provides a single point of entry into the UK healthcare system that cuts out the inherent complexities and inefficiencies of dealing with many and varied stakeholders within the combined medical and academic network on an individual and center by center basis.
Teva has an extensive clinical stage pipeline that is being developed globally and as part of this collaboration plans to spend approximately $20 million on conducting trials in the UK. This agreement enables Teva to benefit from the NIHR’s new translational research infrastructure, its ability to set-up and deliver studies, and access to well characterized cohorts of patients from within the National Health Service
Teva has committed to a three-year dementia research program, providing funding of up to $1 million for early-stage work in UK academic and medical centers. This work will be focused on understanding targets, mechanisms and new approaches to treatment of different causes and types of dementia. As part of the agreement, NOCRI will facilitate Teva's access to the NIHR Biomedical Research Centers and Units in Dementia and Translational Research Partnership in Dementia. Teva will maintain the right to negotiate licenses to these targets.